CLINICAL_TRIALS
trial_result
· 2016-06-10
Clinical Trial Update: Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients [Phase 3]
Summary
Pfizer's Phase 3 trial of bapineuzumab for Alzheimer's disease was terminated and results were posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Alzheimer Disease | Phase 3 | Status: TERMINATED | Results posted: 2016-06-10